Characteristics of Patients Comparing Pembrolizumab plus Chemotherapy or Pembrolizumab alone with Chemotherapy in Included Trials

Source	Histology	Therapeutic regimen	Chemotherapy Drug	No. of patients		NO. of response		PFSa(m)	HR for PFS	OSa(m)	HR for OS	Median Follow-up time (m)
Source	Histology	Therapeutic regimen	Chemotherapy Drug	Pem/Pem + Chemo	Chemo	Pem/Pem + Chemo	Chemo	PFSa(m)	HR for PFS	OSa(m)	HR for OS	Median Follow-up time (m)
KEYNOTE-0212016, 2018	nonsquamous	Pem + Chemo vs. Chemo	AC1) carboplatin (5 mg/ml/min Q3W)2) pemetrexed (500 mg/m^2 Q3W)	20	17	16	6	NR	NR	NR	NR	23.9
KEYNOTE-1892018	nonsquamous	Pem + Chemo vs. Chemo	AP or AC1) cisplatin (75 mg/m^2 Q3W) or carboplatin (6 mg/ml/min Q3W)2) pemetrexed (500 mg/m^2 Q3W)	132	70	81	16	NR	0.36 (0.25–0.52)	NR	0.42 (0.26–0.68)	10.5
KEYNOTE-4072018	squamous	Pem + Chemo vs. Chemo	PC1) carboplatin (6 mg/ml/min Q3W)2) paclitaxel(200 mg/m^2 Q3W) or nab-paclitaxel (100 mg/m^2 Q1W)	73	73	44	24	8.0 vs. 4.2	0.37 (0.24–0.58)	NR	0.64 (0.37–1.10)	7.8
KEYNOTE-0242016, 2017	suqamous and nonsquamous	Pem vs. Chemo	AP or AC or PC or GP or GC1) cisplatin (75 mg/m^2 Q3W) or carboplatin (5-6 mg/ml/min Q3W)2) pemetrexed (500 mg/m^2 Q3W) or paclitaxel (200 mg/m^2 Q3W) or Gemicitabine (1250 mg/m2 d1,8 of Q3W)	154	151	70	45	10.3 vs. 6.0	0.50 (0.37–0.68)	30.0 vs. 14.2	0.63 (0.47–0.86)	25.2
KEYNOTE-0422018	suqamous and nonsquamous	Pem vs. Chemo	AC or PC1) carboplatin (5-6 mg/ml/min Q3W)2) pemetrexed (500 mg/m^2 Q3W) or paclitaxel (200 mg/m^2 Q3W)	299	300	118	96	7.1 vs. 6.4	0.81 (0.67–0.99)	20.0 vs. 12.2	0.69 (0.56–0.85)	12.8

^aData presented as “Pem/Pem + Chemo vs. Chemo”

Abbreviation: Pem Pembrolizumab, Chemo Chemotherapy, NR Not Reported, HR Hazard Ratio, PFS Progression-free Survival, OS Overall survival;